Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques - ScienceDirect
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial | Nature Medicine
Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells | Science
Cells | Free Full-Text | Differences in the Concentration of Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 Recovery or Post-Vaccination | HTML
Biomedicines | Free Full-Text | Long Term Pharmacological Perturbation of Autophagy in Mice: Are HCQ Injections a Relevant Choice? | HTML
immunity – NIH Director's Blog
Vaccines | Free Full-Text | Significant Increase in Antibody Titers after the 3rd Booster Dose of the Pfizer–BioNTech mRNA COVID-19 Vaccine in Healthcare Workers in Greece | HTML
Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection | Science Translational Medicine
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial | Nature Medicine
Lobmeyr Crystal Candy Dish Flat | Available at Kneen & Co
An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates - ScienceDirect
TropicalMed | Free Full-Text | Humoral Immune Response Induced by the BBIBP-CorV Vaccine (Sinopharm) in Healthcare Workers: A Cohort Study | HTML
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults | NEJM
Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2–experienced individuals | Science Translational Medicine
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection | Science
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -
Vaccines | Free Full-Text | Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers | HTML
Tranexamic acid for prevention of hemorrhage in elective repeat cesarean delivery—a randomized study - American Journal of Obstetrics & Gynecology MFM
Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis - ScienceDirect
Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary - Journal of Infection
PRECLINICAL AND CLINICAL DEVELOPMENT OF ABBV-8E12, A HUMANIZED ANTI-TAU ANTIBODY, FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER TAUOPATHIES • The Journal of Prevention of Alzheimer's Disease
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -
Drug-induced corneal deposits: an up-to-date review | BMJ Open Ophthalmology
Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2–experienced individuals | Science Translational Medicine
Vaccines | Free Full-Text | Significant Increase in Antibody Titers after the 3rd Booster Dose of the Pfizer–BioNTech mRNA COVID-19 Vaccine in Healthcare Workers in Greece | HTML
Omecamtiv mecarbil does not prolong QTc intervals at therapeutic concentrations - Trivedi - - British Journal of Clinical Pharmacology - Wiley Online Library
A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2 - ScienceDirect
